SNDX
Syndax Pharmaceuticals, Inc.
There isn't enough reported data to score SNDX yet.
SNDX Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Unavailable | |
| Unavailable |
SNDX's revenue is currently healthy, but its profitability is under pressure. There isn't enough data to rate its cash flow and balance sheet.
SNDX PE Valuation
SNDX has no meaningful PE right now: it lost money over the past year.
SNDX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect SNDX's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
SNDX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.36 | +$1.24 |
| Q2 2026 | -$2.51 | +$1.37 |
| Q1 2026 | -$2.79 | +$1.06 |
| Q4 2025 | -$3.29 | +$0.43 |
| Q3 2025 | -$3.60 | +$0.05 |
| Q2 2025 | -$3.88 | -$0.48 |
| Q1 2025 | -$3.85 | -$0.61 |
| Q4 2024 | -$3.72 | -$0.74 |
SNDX is still losing money, but less than at its worst: $2.36 per share over the past year, against $3.88 at its worst in mid-2025.
SNDX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $83.3M | +82% |
| Q2 2026 | $72.8M | +92% |
| Q1 2026 | $64.9M | +224% |
| Q4 2025 | $68.7M | +795% |
| Q3 2025 | $45.9M | +267% |
| Q2 2025 | $38M | +985% |
| Q4 2021 | $126.6M | +33209% |
| Q3 2021 | $12.4M | +3165% |
SNDX's revenue is recovering but still below its 2021 peak: $83M last quarter, up 82% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -50% | +75 points |
| Q2 2026 | -55% | +128 points |
| Q1 2026 | -53% | +365 points |
| Q4 2025 | -91% | +1164 points |
| Q3 2025 | -125% | +591 points |
| Q2 2025 | -183% | +1938 points |
| Q1 2025 | -418% | N/A |
| Q4 2024 | -1255% | N/A |
SNDX's operating margin was −50% last quarter, up 75 points from the same quarter a year ago.
SNDX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$27.3M | +$43.3M |
| Q2 2026 | -$30.3M | +$57.5M |
| Q1 2026 | -$50.3M | +$44.8M |
| Q3 2025 | -$70.5M | -$8.2M |
| Q2 2025 | -$87.8M | -$16.2M |
| Q1 2025 | -$95.2M | -$11.6M |
| Q3 2024 | -$62.3M | -$17.7M |
| Q2 2024 | -$71.6M | -$36.3M |
SNDX has burned cash in almost every quarter: −$178M over the past year, against −$303M the year before.
SNDX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +799K shares |
| 1 year | +3.7% | +3.2M shares |
| 3 years | +29% | +19.9M shares |
| 5 years | +73% | +37.8M shares |
| Available history | +184% | +58.1M shares |
SNDX has 90M diluted shares, up 3.7% from a year ago.
SNDX Net Leverage
SNDX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
SNDX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 26.3 | Oversold |
| Stochastic | 5.3 | Oversold |
SNDX's weekly RSI is 26 (oversold) and its Stochastic is 5 (oversold).
SNDX PE vs Healthcare Sector
| Metric | SNDX | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
SNDX has no meaningful PE right now: it lost money over the past year.
SNDX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $14.0 | 32% below |
| 20 week MA | $17.8 | 46% below |
| 50 week MA | $19.8 | 52% below |
| 100 week MA | $16.6 | 42% below |
| 200 week MA | $18.4 | 48% below |
SNDX is in a downtrend: it's below all five of its weekly moving averages, and 48% below its 200-week average.
SNDX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $8.94 | $24.2 | +171% |
| 2021 | $24.2 | $22.5 | -7.1% |
| 2022 | $22.5 | $24.3 | +8.1% |
| 2023 | $24.3 | $21.6 | -11% |
| 2024 | $21.6 | $12.8 | -41% |
| 2025 | $12.8 | $21.3 | +67% |
| 2026 YTD | $21.3 | $9.54 | -55% |
SNDX's yearly returns have swung widely, from +171% in 2020 to −41% in 2024. It's down 55% so far in 2026.